title: [Efficacy of dorzolamide in reducing retinal thickness after photocoagulation in diabetic macular oedema].
abstract: BACKGROUND
  Focal photocoagulation interrupts vascular leakage in diabetic macular edema, and allows the retinal pigment epithelium to withdraw fluid that thickens the retina; this mechanism could be enhanced by dorzolamida, a topical carbonic anhydrase inhibitor.
  
  
  OBJECTIVE
  To determine the efficacy of dorzolamida compared against placebo, in reducing retinal thickness after focal photocoagulation, in eyes with diabetic macular oedema.
  
  
  METHODS
  Experimental, comparative, prospective, longitudinal, double blind study in diabetics with focal macular oedema treated with photocoagulation. Treated eyes were randomly assigned three weeks after the procedure to receive dorzolamide (group 1) or placebo (group 2), three times daily during three weeks. Means of visual acuity, center point thickness and macular volume were compared 3 and 6 weeks after photocoagulation within groups (Wilcoxon's t) and between groups (Mann-Whitneys's U).
  
  
  RESULTS
  Sixty-nine eyes form patients aged 58.3 ± 8.3 years; 37 were assigned to group 1 and 42 to group 2. Mean center point thickness changed from 178.4 ± 34μm to 170 ± 29.1μm in group 1 (p = 0.04), and from 179.2 ± 22.4μm to 178.6 ± 20.8μm in group 2 (p = 0.7); mean macular volume changed from 7.63 ± 0.52mm(3) to 7.50 ± 0.50mm(3) in group 1 (p = 0.02) and from 7.82 ± 0.43mm(3) to 7.76 ± 0.42mm(3) in group 2 (p = 0.014).
  
  
  CONCLUSIONS
  The efficacy of dorzolamide was higher than that of placebo, to reduce retinal thickness after focal photocoagulation in diabetics with macular oedema.
authors.affiliation: Servicio de Oftalmología, Hospital Juárez de México, México DF, México.
authors.forename: Virgilio
authors.initials: V
authors.lastname: Lima-Gómez
authors.affiliation: Escuela de Medicina, Universidad Justo Sierra, México DF, México.
authors.forename: Diana Alejandra
authors.initials: DA
authors.lastname: Bermúdez-Zapata
authors.affiliation: División de Investigación, Hospital Juárez de México, México DF, México. Electronic address: razoblanco.dulce@gmail.com.
authors.forename: Dulce Milagros Razo
authors.initials: DM
authors.lastname: Blanco-Hernández
mesh_terms: D000328:Adult; D000368:Aged; D000886:Anthropometry; D001082:Aqueous Humor / Q000378:metabolism; D001692:Biological Transport; D002257:Carbonic Anhydrase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003930:Diabetic Retinopathy / Q000473:pathology / Q000601:surgery*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007249:Inflammation; D007429:Intraocular Pressure; D008028:Light Coagulation / Q000009:adverse effects; D008269:Macular Edema / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D008297:Male; D008833:Microcirculation; D008875:Middle Aged; D011142:Polyvinyl Alcohol / Q000627:therapeutic use; D011182:Postoperative Care / Q000379:methods*; D012160:Retina / Q000187:drug effects* / Q000473:pathology; D055213:Retinal Pigment Epithelium / Q000187:drug effects / Q000503:physiopathology; D012171:Retinal Vessels / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*; D013876:Thiophenes / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D013449:Sulfonamides; D013876:Thiophenes; D011142:Polyvinyl Alcohol; C062765:dorzolamide
keywords: Diabetic macular edema; Diabetic retinopathy; Dorzolamida; Dorzolamide; Edema macular diabético; Fotocoagulación; Photocoagulation; Retinopatía diabética